[Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]

Calderón M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001163
Authors' recommendations: The evidence found supporting the use of ceritinib in patients with metastatic ALK+ lung cancer is limited and of low methodological quality. No randomized controlled clinical trials were found assessing the efficacy and safety of ceritinib. Lack of information on its impact on survival and quality of life in good quality controlled studies, limits its recommendation as a treatment of choice. Few international societies and US private health sponsors consider it as a therapeutic alternative for patients with disease progression or intolerance to the use of crizotinib.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Antineoplastic Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.